Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.

In a more challenging regulatory environment for clinical trials, optimising trial designs early makes success more likely.

In a report released yesterday, Derek Archila from Wells Fargo maintained a Hold rating on Incyte, with a price target of $100.00. The company’s shares closed yesterday at $67.67. According to ...

Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...

Sino Biopharmaceuticals plans to pay up to nearly $951 million to acquire LaNova Medicines, which previously licensed drugs ...

Several SDGs are directly linked to taxation, especially those focused on poverty, hunger, health, education, equality, and ...

The World Bank’s 2025 Country Policy and Institutional Assessment (CPIA) Africa Report has issued a resounding wake-up call: governments must urgently improve service delivery to meet the needs of ...

Learn what biotechnology is with simple explanations and fascinating examples! Discover hands-on science project ideas for ...

The EU has previously talked up agriculture as a key security concern. In the crisis preparedness plan presented last March, ...

The 10-Year Health Plan paints a picture of a health service in 2035 that is prevention-focused, community-based and ...